Pituitary adenoma laboratory tests

Revision as of 13:21, 18 August 2015 by Ahmad Al Maradni (talk | contribs)
Jump to navigation Jump to search

Pituitary adenoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pituitary adenoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural history, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pituitary adenoma laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pituitary adenoma laboratory tests

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pituitary adenoma laboratory tests

CDC on Pituitary adenoma laboratory tests

Pituitary adenoma laboratory tests in the news

Blogs on Pituitary adenoma laboratory tests

Directions to Hospitals Treating Pituitary adenoma

Risk calculators and risk factors for Pituitary adenoma laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Laboratory Findings

The diagnosis is generally entertained either on the basis of visual difficulties arising from the compression of the optic nerve by the tumor, or on the basis of manifestations of excess hormone secretion: the specifics depend on the type of hormone. The specific area of the visual pathway at which compression by these tumours occurs is at the optic chiasma.

Tumors which cause visual difficulty are likely to be macroadenomata greater than 10 mm in diameter; tumors less than 10 mm are microadenomata.

Some tumors secrete more than one hormone, the most common combination being GH and prolactin.

Prolactinomas are frequently diagnosed during pregnancy, when the hormone progesterone increases the tumor's growth rate. The diagnosis is confirmed by testing hormone levels, and by radiographic imaging of the pituitary (for example, by CT scan or MRI).

References